Clinical trial
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With…
NCT00109109 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00109109 |
|---|---|
| Title | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004) |
| Official title | Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment - Up to 8 Cycles or 6 months |
| Enrollment | 60 |
| Start date | Dec 1, 2003 |
| Primary completion | Feb 14, 2006 |
| Completion | Feb 14, 2006 |
| First posted | Apr 25, 2005 |
| Last update posted | Nov 14, 2019 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: